Drug: Terapia asistida con MDMA

What It Is

MDMA-assisted therapy is a supervised treatment studied for post-traumatic stress disorder, in which a screened patient takes MDMA a small number of times inside a course of psychotherapy. The drug is not taken alone or repeatedly. Each person first has preparatory sessions, then day-long dosing sessions with two therapists present, then integration sessions afterward to work through what came up. The broader overview of psilocybin, ketamine, and the whole field sits on the psychedelics page.

MDMA (3,4-methylenedioxymethamphetamine) is the same compound sold illegally as ecstasy or molly. The studied treatment and recreational use share only the molecule: different doses, medical screening, monitoring, and a structured course of therapy.

What It Does

Two phase 3 trials provide the main evidence. In the first, MAPP1, ninety adults with severe PTSD were randomized either to three MDMA sessions plus therapy or to identical therapy with an inactive placebo. PTSD severity is measured on the CAPS-5 scale, which runs from 0 to 80. It fell 24.4 points with MDMA against 13.9 with placebo, a between-group effect size of d=0.91. The second trial, MAPP2, enrolled a more diverse group of 104 people with moderate-to-severe PTSD. It found a smaller but still clear benefit: a CAPS-5 drop of 23.7 points against 14.8, d=0.7. Both trials also improved day-to-day functioning, and both were generally well tolerated over the study period.

One problem weakens every psychedelic trial, including these two: the blinding fails. MDMA produces effects a person notices, so in a trial almost everyone can tell whether they got the drug or the placebo. A 2026 systematic review found that in inert-placebo MDMA trials more than 85 percent of participants correctly guessed their assignment. Across the wider set of psychedelic trials, most did not even measure blinding. This is called functional unblinding: when a person knows they received a treatment they hoped would work, expectation can lift their scores. It does not mean the benefit is absent, but the measured size of the effect is likely inflated.

This is called functional unblinding: when a person knows they received a treatment they hoped would work, expectation can lift their scores. It does not mean the benefit is absent, but the measured size of the effect is likely inflated.

The clearest check on overstatement came from regulators. Despite the two positive trials, the FDA declined approval in 2024 and called for a fresh phase 3 study. Regulators cited the weak blinding, the lack of an active comparator, thin data on the benefit's durability, and questions about how the trials were run.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Evidence And Methods

In MDMA trials most participants and raters correctly guess who received the drug, which inflates the measured benefitModerate · mixed

In plain terms

In MDMA trials almost everyone can tell whether they got the drug, which lets expectation inflate the measured benefit.

In detail

The PRISMA systematic review covered 112 randomized trials of psychedelics for psychiatric disorders (11 MDMA, plus psilocybin, LSD, ketamine, ayahuasca, DMT). Functional unblinding, defined as participants or raters correctly identifying treatment allocation from subjective effects, was pervasive; inert-placebo-controlled MDMA trials exceeded 85%. The review concluded that this pervasive unblinding raises concerns about the validity of efficacy findings.

The study · 1

Orsini et al., blinding integrity in psychedelic randomized clinical trials, a systematic review · JAMA Psychiatry 2026 (online)

In 2024 the FDA declined to approve MDMA-assisted therapy for PTSD and asked for another trialModerate · mixed

In plain terms

Regulators judged the two positive trials not yet convincing enough and asked for another one before any approval.

In detail

A 2026 commentary in the trauma-stress literature, responding to a State of the Science review of MDMA-assisted psychotherapy, argued that the evidence base remains constrained by difficulties in blinding, expectancy effects, the absence of robust active comparators, limited mechanistic clarity, and concerns about safety monitoring and generalizability, and that durability of gains, not short-term symptom reduction should be the standard for adoption. These are the same dimensions the FDA cited in declining approval and requesting a further trial.

The study · 1

Suhardita et al., from therapeutic promise to evidentiary discipline, reassessing MDMA-assisted psychotherapy · J Trauma Stress 2026

How it works

MDMA releases serotonin along with dopamine and noradrenaline, lowering fear and raising trustModerate · mixed

In plain terms

MDMA floods the brain with serotonin, which lowers fear and raises trust, making painful memories easier to work through in therapy.

In detail

MDMA acts mainly by triggering release of serotonin through the serotonin transporter, along with dopamine and noradrenaline. The serotonin rise lowers the brain's fear response and raises feelings of trust and closeness, which is the basis for using it to help people stay with traumatic memories during therapy. The link from this pharmacology to durable symptom change is still being worked out, and the same monoamine release drives the acute cardiovascular and temperature effects.

The study · 1

Nichols, psychedelics, a comprehensive review · Pharmacol Rev 2016;68:264-355

Mood & stress

MDMA-assisted therapy lowered severe PTSD scores more than placebo with therapy in a phase 3 trialEmerging

In plain terms

In a phase 3 trial, adding MDMA to a course of therapy eased severe PTSD more than the same therapy with a placebo.

In detail

This randomized, double-blind, placebo-controlled multi-site phase 3 trial (NCT03537014) enrolled 90 adults with severe PTSD, including people with dissociation, depression, and substance-use histories. After medication washout, participants were randomized 1:1 to manualized therapy with MDMA or with placebo, each combined with three preparatory and nine integrative sessions. Mean CAPS-5 change in completers was -24.4 (SD 11.6) with MDMA and -13.9 (SD 11.5) with placebo. MDMA did not induce adverse events of abuse potential, suicidality, or QT prolongation over the study.

The study · 1

Mitchell et al., MDMA-assisted therapy for severe PTSD, a randomized double-blind placebo-controlled phase 3 study · Nat Med 2021;27:1025-1033

A confirmatory phase 3 trial again found MDMA-assisted therapy beat placebo with therapy for moderate-to-severe PTSDEmerging

In plain terms

A second phase 3 trial in a more diverse group again found MDMA plus therapy eased PTSD more than therapy with a placebo, by a somewhat smaller amount.

In detail

This randomized, placebo-controlled phase 3 trial (NCT04077437) enrolled 104 adults, of whom 26.9% had moderate and 73.1% had severe PTSD; 33.7% identified as other than White. Participants were randomized to MDMA-assisted therapy (n=53) or placebo with therapy (n=51), assessed by blinded independent raters. LS mean CAPS-5 change was -23.7 (95% CI -26.94 to -20.44) with MDMA versus -14.8 (95% CI -18.28 to -11.28) with placebo. Seven participants had a severe treatment-emergent adverse event (5 MDMA, 2 placebo); there were no deaths or serious adverse events.

The study · 1

Mitchell et al., MDMA-assisted therapy for moderate to severe PTSD, a randomized placebo-controlled phase 3 trial · Nat Med 2023;29:2473-2480

Cognition

Heavy recreational MDMA use may harm serotonin neurons, but human evidence is confounded by polydrug usePreliminary · risk

In plain terms

Heavy ecstasy use may harm serotonin-releasing neurons and memory, but the human evidence is tangled up with other drug use.

In detail

MDMA causes lasting reductions in serotonin markers in animals, including primates, and some studies link heavy recreational ecstasy use to cognitive and neuroimaging changes. In humans this is difficult to establish, because most heavy users also take other drugs and the research relies on self-reported past use. The neurotoxicity seen in animals used higher and more frequent doses than a supervised therapeutic session, and confounding by polydrug use and reliance on self-report weaken the human cognitive findings.

The study · 1

Montgomery et al., neurological and cognitive alterations induced by MDMA in humans · Exp Neurol 2022;347:113888

How It Works

MDMA acts mainly on one neurotransmitter: it makes the brain release a surge of serotonin, along with dopamine and noradrenaline. The rise in serotonin dampens the fear response and raises feelings of trust and closeness. With that fear dampened and a trusted therapist in the room, a person can turn toward a traumatic memory and stay with it long enough to process it. The aim is a change that outlasts the drug, produced by the therapy sessions themselves.

What Happens Across a Course of Treatment

1The single session

MDMA reaches its peak effect over a few hours. During those hours a person can approach memories that trauma normally keeps out of reach. The rise in noradrenaline also raises heart rate, blood pressure, and body temperature. Medical monitoring is part of the studied setting for that reason.

2Between and after sessions

The MDMA sessions were spaced weeks apart, each followed by drug-free integration therapy. The reprocessing happens in that later therapy. Recreational use follows a different pattern, with the same dose taken often and without support.

3The unresolved part

How a few sessions produce lasting change is still unclear, and whether the benefit holds past the trial's end is unknown. The pharmacology is well described; the path from a serotonin rise to lasting recovery is not yet understood.

The Legal Position

The trials are positive; the drug remains illegal to use. In the United States MDMA is Schedule I federally, the most restricted category, so use outside an authorized research or approved-treatment setting is illegal. There is no state-regulated adult-use framework for MDMA of the kind Oregon and Colorado created for psilocybin. Because the FDA has not approved it, MDMA-assisted therapy is reachable only inside clinical trials and expanded-access programs.

The Chinese Medicine View

Chinese medicine has a long-standing frame for altered states of mind, and it leans toward caution. The Heart is said to house the Shen, the spirit or consciousness. Clear thought, steady emotion, and restful sleep are read as three signs of a settled Shen. A mind flooded, disoriented, or thrown into fear is a disturbed Shen, and the classical tradition works to calm and anchor it.

Trauma, in this language, reads as a lasting disturbance of the Shen, and often of the Heart and Kidney together. The classical bias is toward grounding: settling the Shen, harmonizing the Heart, and rooting a scattered mind back in the body through stillness, breath, and regular life. In this frame a deliberately mind-altering session is a serious intervention on an already disturbed Shen, one the tradition approaches with care and skilled support. The clinical evidence points the same way: preparation, support, and a stable setting shape the outcome. The wider preventive tradition of Yang Sheng, nourishing life, would place grounding practices first.

Cautions For This Practice

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

MDMA raises core body temperature and can cause dangerous hyperthermia at higher recreational doses

In controlled laboratory studies MDMA produced a dose-dependent rise in core body temperature of about 0.2 to 0.8 degrees C, and temperatures above 38 degrees C occurred often at higher doses even at rest and at room temperature. Severe hyperthermia is one of the recognized life-threatening complications of recreational MDMA use. The lab rises were modest and did not reach hyperpyrexia in a controlled setting; the severe cases come from higher uncontrolled doses, physical exertion, and hot environments.Liechti, effects of MDMA on body temperature in humans

Repeated full-dose MDMA is linked to heart-valve damage through the 5-HT2B receptor

MDMA is a partial agonist at the 5-HT2B serotonin receptor, the receptor tied to valvular heart disease from other drugs, and chronic ingestion of full doses of MDMA has been associated with valvular heart disease. The risk from single supervised therapeutic sessions has not been directly measured. No study designed to measure valve risk from therapeutic dosing exists, and the concern attaches to frequent or repeated use, not the few sessions used in the trials.Tagen et al., the risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Not an approved or legal treatment

There is no dosing, sourcing, or instruction anywhere here. The trial results come from screened patients, prepared sessions, trained therapists, and medical monitoring. Taking the drug alone or at a party is a different situation entirely.

Acute cardiovascular and temperature strain

Severe hyperthermia is a recognized life-threatening complication at higher uncontrolled doses, made worse by exertion and hot rooms. Drinking too much water to counter that heat has caused dangerous hyponatremia, a fall in blood sodium that can lead to seizures. Anyone with heart disease or a heat-sensitive condition is at higher risk.

Serotonin syndrome and drug interactions

Because MDMA releases serotonin, combining it with an MAOI antidepressant or other strongly serotonergic drugs can push serotonin to dangerous levels, a state called serotonin syndrome. SSRIs and SNRIs can also blunt the effect. The trials washed medications out under supervision for that reason. Anyone on psychiatric medication faces possible drug interactions and should not stop or combine drugs without a prescriber's guidance.

Who should not do this, and the neurotoxicity question

A personal or family history of bipolar disorder or of psychosis is the most important reason for caution, because these drugs can trigger mania or psychosis in vulnerable people. Heavy repeated recreational use is linked to lasting reductions in serotonin markers in animals and to cognitive changes in some human studies. That human evidence is confounded by polydrug use. The neurotoxicity concern attaches to frequent high-dose use, a far heavier exposure than the trials' small number of monitored sessions.

MDMA-assisted therapy is a promising area of trauma research, and MDMA is a potent drug. It carries real acute risks, and longer-term risks at heavy repeated exposure. For anything touching your own care or medication, talk it through with a qualified clinician.

Common Questions

Does MDMA-assisted therapy work for PTSD?

Likely yes. Standard PTSD treatment leaves many people symptomatic for years, so even a partial new option draws attention.

If the trials were positive, why did the FDA say no?

The FDA never questioned the drug's safety. It objected that patients can feel the drug, so the trials cannot be truly blinded, and asked for a study that fixes this.

How is MDMA different from psilocybin or ketamine?

They get grouped together but act on different systems. MDMA works mainly through serotonin release and is the one studied for PTSD. Psilocybin acts on the serotonin 5-HT2A receptor and is studied for depression and end-of-life distress. Ketamine and its approved relative esketamine act on the NMDA glutamate receptor and work fast on mood. The psychedelics overview covers them in full.

Is MDMA dangerous?

Yes. One idea organizes the specific dangers: risk scales with dose and setting.

Go Deeper

• Psychedelics in mental health: the overview of the whole field, including psilocybin for depression, the approved relative esketamine, the blinding problem, and where the law stands.
• Anxiety: the condition that runs alongside much of this research, and the treatments with the strongest track record. PTSD is closely related, and the same grounding practices apply.